Microtubule dynamics as a target in oncology

Cancer Treatment Reviews

Volumn 35, Issue 3, 2009, Pages 255-261

  Risinger, April L ^a,b   Giles, Francis J ^b   Mooberry, Susan L ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

2 Methoxyestradiol; Colchicine; Discodermolide; Epothilone; Halichondrin B; Microtubule; Microtubule targeting agent; Taccalonolide; Taxane; Vinca alkaloid

Indexed keywords

ALOCREST; ALPHA TUBULIN; BETA TUBULIN; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; COLCHICINE; COMBRETASTATIN A4 PHOSPHATE; CRYPTOPHYCIN 52; DOCETAXEL; EPOTHILONE B; ERIBULIN; GEMCITABINE; GLYCOPROTEIN P; HALICHONDRIN B; IXABEPILONE; LAROTAXEL; LAULIMALIDE; MARQIBO; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NAVELBINE; PACLITAXEL; SAGOPILONE; SOBLIDOTIN; TALTOBULIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE SULFATE; VINCRISTINE SULFATE; VINDESINE; VINFLUNINE;

ACUTE LYMPHOCYTIC LEUKEMIA; BINDING SITE; BLADDER CANCER; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; DISEASE MODEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MOLECULAR MECHANICS; NEUROLOGIC DISEASE; OVARY CANCER; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PROSTATE CANCER; PROTEIN BINDING; REVIEW; SARCOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL DIVISION; CLINICAL TRIALS AS TOPIC; COLCHICINE; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; EPOTHILONES; HUMANS; LACTONES; MACROLIDES; MICROTUBULES; NEOPLASMS; STEROIDS; TAXOIDS; TUBULIN MODULATORS; VINCA ALKALOIDS;

EID: 64049097460     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.11.001     Document Type: Review

References (100)

1. Lopez-Fanarraga M., Avila J., Guasch A., Coll M., and Zabala J.C. Review: postchaperonin tubulin folding cofactors and their role in microtubule dynamics. J Struct Biol 135 2 (2001) 219-229
2. Nogales E., and Wang H.W. Structural mechanisms underlying nucleotide-dependent self-assembly of tubulin and its relatives. Curr Opin Struct Biol 16 2 (2006) 221-229
3. Jordan M.A., and Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7 8 (2007) 730-742
4. Rusan N.M., Fagerstrom C.J., Yvon A.M., and Wadsworth P. Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin. Mol Biol Cell 12 4 (2001) 971-980
5. Okouneva T., Hill B.T., Wilson L., and Jordan M.A. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2 5 (2003) 427-436
6. Kelling J., Sullivan K., Wilson L., and Jordan M.A. Suppression of centromere dynamics by Taxol in living osteosarcoma cells. Cancer Res 63 11 (2003) 2794-2801
7. Cutts J.H., Beer C.T., and Noble R.L. Biological properties of vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action. Cancer Res 20 (1960) 1023-1031
8. Gigant B., Wang C., Ravelli R.B., et al. Structural basis for the regulation of tubulin by vinblastine. Nature 435 7041 (2005) 519-522
9. Lin C.M., and Hamel E. Effects of inhibitors of tubulin polymerization on GTP hydrolysis. J Biol Chem 256 17 (1981) 9242-9245
10. Toso R.J., Jordan M.A., Farrell K.W., Matsumoto B., and Wilson L. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 32 5 (1993) 1285-1293
11. Takanari H., Yosida T., Morita J., Izutsu K., and Ito T. Instability of pleomorphic tubulin paracrystals artificially induced by Vinca alkaloids in tissue-cultured cells. Biol Cell 70 1-2 (1990) 83-90
12. Thomas DA. Safety and efficacy of marquibo (vincristine sulfate liopsomes injection, OPISOME (TM)) for the treatment of adults with relapsed or refractory acute lymphoblastic leukemia (ALL). In: American Society of Hemotology. 2007; Atlanta, GA.
13. Clinical Trials. gov. National Institutes of Health. http://clinicaltrials.gov; 2008.
14. Product Pipeline. Tekmira Pharmaceuticals Corporation. www.tekmirapharm.com/programs/pipeline.asp; 2008.
15. Yun-san Yip A., Yuen-Yuen Ong E., and Chow L.W. Vinfluine: clinical perspectives of an emerging anticancer agent. Expert Opin Invest Drugs 17 4 (2008) 583-591
16. Dabydeen D.A., Burnett J.C., Bai R., et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70 6 (2006) 1866-1875
17. Bai R.L., Pettit G.R., and Hamel E. Binding of dolastatin-10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265 28 (1990) 17141-17149
18. Hadaschik B.A., Adomat H., Fazli L., et al. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. Clin Cancer Res 14 5 (2008) 1510-1518
19. Margolin K., Longmate J., Synold T.W., et al. Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs 19 (2001) 335-340
20. Vaishampayan U., Glode M., Du W., et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res 6 11 (2000) 4205-4208
21. Hoffman M.A., Blessing J.A., and Lentz S.S. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol 89 1 (2003) 95-98
22. Krug L.M., Miller V.A., Kalemkerian G.P., et al. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann Oncol 11 2 (2000) 227-228
23. Mross K., Berdel W.E., Fiebig H.H., et al. Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society. Ann Oncol 9 12 (1998) 1323-1330
24. Mita A.C., Hammond L.A., Bonate P.L., et al. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res 12 17 (2006) 5207-5215
25. Garg V., Zhang W., Gidwani P., Kim M., and Kolb E.A. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clin Cancer Res 13 18 Pt 1 (2007) 5446-5454
26. Smith C.D., Zhang X., Mooberry S.L., Patterson G.M., and Moore R.E. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res 54 14 (1994) 3779-3784
27. Smith CD, Zhang X. Mechanism of action cryptophycin. Interaction with the vinca alkaloid domain of tubulin. J Biol Chem 1996;271(11):6192-8.
28. Edelman M.J., Gandara D.R., Hausner P., et al. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung cancer 39 2 (2003) 197-199
29. Ravelli R.B., Gigant B., Curmi P.A., et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428 6979 (2004) 198-202
30. Brossi A., Yeh H.J., Chrzanowska M., et al. Colchicine and its analogues: recent findings. Med Res Rev 8 1 (1988) 77-94
31. Bhattacharyya B., Panda D., Gupta S., and Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 28 1 (2008) 155-183
32. Ben-Chetrit E., and Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 28 1 (1998) 48-59
33. Kanthou C., and Tozer G.M. Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets 11 11 (2007) 1443-1457
34. Cooney M.M., van Heeckeren W., Bhakta S., Ortiz J., and Remick S.C. Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol 3 12 (2006) 682-692
35. Tozer G.M., Prise V.E., Wilson J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59 7 (1999) 1626-1634
36. Kanthou C., and Tozer G.M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99 6 (2002) 2060-2069
37. Siemann D.W., Mercer E., Lepler S., and Rojiani A.M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99 1 (2002) 1-6
38. Young S.L., and Chaplin D.J. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 13 9 (2004) 1171-1182
39. West C.M., and Price P. Combretastatin A4 Phosphate. Anticancer Drugs 15 3 (2004) 179-187
40. Cooney M.M., Radivoyevitch T., Dowlati A., et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10 1 Pt 1 (2004) 96-100
41. Segreti J.A., Polakowski J.S., Koch K.A., et al. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 54 3 (2004) 273-281
42. Jorgensen T.J., Tian H., Joseph I.B., Menon K., and Frost D. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Cancer Chemother Pharmacol 59 6 (2007) 725-732
43. Morton C.L., Favours E.G., Mercer K.S., et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 25 4 (2007) 285-295
44. Yee K.W., Hagey A., Verstovsek S., et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11 18 (2005) 6615-6624
45. Fox E., Maris J.M., Widemann B.C., et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 14 4 (2008) 1111-1115
46. Mita M. Phase I dose escalation trial with DCE-MRI imaging of the novel vascular disrupting agent NPI-2358. AACR; 2008.
47. LaVallee T.M., Zhan X.H., Herbstritt C.J., et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 62 13 (2002) 3691-3697
48. Mabjeesh N.J., Escuin D., LaVallee T.M., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 4 (2003) 363-375
49. Fotsis T., Zhang Y., Pepper M.S., et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368 6468 (1994) 237-239
50. Dahut W.L., Lakhani N.J., Gulley J.L., et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5 1 (2006) 22-27
51. James J., Murry D.J., Treston A.M., et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 25 1 (2007) 41-48
52. ENMD-1198. Entremed. www.entremed.com/science/enmd-1198; 2008.
53. Lavallee T.M., Burke P.A., Swartz G.M., et al. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 7 6 (2008) 1472-1482
54. ® (2ME2) for Rheumatoid Arthritis. Entremed. www.entremed.com/science/panzem; 2008.
55. LP-251. Locus Pharmaceuticals. http://www.locuspharmaceuticals.com/programs/lp-261; 2008.
56. Elie-Caille C., Severin F., Helenius J., et al. Straight GDP-Tubulin Protofilaments Form in the Presence of Taxol. Curr Biol 17 (2007) 1765-1770
57. Andru J.M., Bordas J., Diaz J.F., et al. Low Resolution structure of microtubules in solution. Synchrotron X-ray scattering and electron microscopy of taxol-induced microtubules assembled from purified tubulin in comparison with glycerol and MAP-induced microtubules. J Mol Biol 226 1 (1992) 169-184
58. Rao S., Chakravarty S., et al. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol. J Biol Chem 274 53 (1999) 37990-37994
59. Montero A., Fossella F., Hortobagyi G., and Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6 4 (2005) 229-239
60. Leonard G.D., Fojo T., and Bates S.E. The role of ABC transporters in clinical practice. Oncologist 8 5 (2003) 411-424
61. Trock B.J., Leonessa F., and Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Nat Cancer Inst 89 (1997) 917-931
62. Chiou J.F., Liang J.A., Hsu W.H., et al. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 181 5 (2003) 267-273
63. Rottenberg S., Nygren A.O., Pajic M., et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 104 29 (2007) 12117-12122
64. Seve P., and Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol 9 2 (2008) 168-175
65. Risinger A.L., Jackson E.M., Polin L.A., et al. The Taccalonolides:Microtubule Stabilizers that Circumvent Clinically Relevant Taxane Resistance Mechanisms. Cancer Res 68 21 (2008) 8881-8888
66. Orr G.A., Verdier-Pinard P., McDaid H., and Horwitz S.B. Mechanisms of Taxol resistance related to microtubules. Oncogene 22 47 (2003) 7280-7295
67. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 31 (2005) 7794-7803
68. Demeule M., Regina A., Che C., et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 324 3 (2008) 1064-1072
69. Regina A., Demeule M., Che C., et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 155 2 (2008) 185-197
70. Dieras V., Limentani S., Romieu G., et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol (2008) 1064-1072
71. TPI 287. Tapestry Pharmaceuticals. www.tapestrypharma.com/TPI287; 2008.
72. Zatloukal P., Gervais R., Vansteenkiste J., et al. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol 3 8 (2008) 894-901
73. Kowalski R.J., Giannakakou P., and Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 272 4 (1997) 2534-2541
74. Bode C.J., Gupta Jr. M.L., Reiff E.A., et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 41 12 (2002) 3870-3874
75. Altmann K.H., Wartmann M., and O'Reilly T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470 3 (2000) M79-91
76. Pazdur R, Keegan P. FDA Approval for Ixabepilone. National Cancer Institute. www.cancer.gov/cancertopics/druginfo/fda-ixabepilone; 2007.
77. Fumoleau P., Coudert B., Isambert N., and Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogs. Ann Oncol 18 suppl 5 (2007) v9-v15
78. Sagopilone shows promise in combating tumors. Bayer. www.research.bayer.com/edition-19/19_Epothilones.pdfx; 2008.
79. Kosan Pipeline, 2008. Kosan Biosciences. www.kosan.com/pipeline.html; 2008.
80. Trivedi M., Budihardjo I., Loureiro K., Reid T.R., and Ma J.D. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncology 4 4 (2008) 483-500
81. Padzur R, Keegan P. FDA approval for Ixabepilone. In: N.C. Institute, editor. Cancer topics. http://www.cancer.gov.cancertopics/druginfo/fda-ixbepilone; 2007.
82. Martello L.A., McDaid H.M., Regl D.L., et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 6 5 (2000) 1978-1987
83. Huang G.S., Lopez-Barcons L., Freeze B.S., et al. Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res 12 1 (2006) 298-304
84. Mita A., Lockhart L., Chen T.-L., et al. A phase I pharmacokinetic (PK) trial of XAA296A (discodermolide) administered every 3 wks to adult patients with advance solid malignancies. J Clin Oncol 22 14S (2004) 2025
85. Madiraju C., Edler M.C., Hamel E., et al. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. Biochemistry 44 45 (2005) 15053-15063
86. Canales A., Matesanz R., Gardner N.M., et al. The bound conformation of microtubule-stabilizing agents: NMR insights into the bioactive 3D structure of discodermolide and dictyostatin. Chemistry 14 25 (2008) 7557-7569
87. Long B., Carboni J., Wasserman A., et al. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res 58 6 (1998) 1111-1115
88. Hamel E., Day B.W., Miller J.H., et al. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol (2006) 457-467
89. Clark E.A., Hills P.M., Davidson B.S., Wender P.A., and Mooberry S.L. Laulimalide and Synthetic Laulimalide Analogues Are Synergistic with Paclitaxel and 2-Methoxyestradiol. Mol Pharm 3 4 (2006) 457-467
90. Lu H., Murtagh J., and Schwartz E.L. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol Pharmacol 69 4 (2006) 1207-1215
91. Mooberry S.L., Tien G., Hernandez A.H., Plubrukarn A., and Davidson B.S. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 59 3 (1999) 653-660
92. Liu J., Towle M., Cheng H., et al. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 27 3B (2007) 1509-1518
93. Johnson T.A., Tenney K., Cichewicz R.H., et al. Sponge-derived fijianolide polyketide class: further evaluation of their structural and cytotoxicity properties. J Med Chem 50 16 (2007) 3795-3803
94. Mooberry S.L., Randall-Hlubek D.A., Leal R.M., et al. Microtubule-stabilizing agents based on designed laulimalide analogues. Proc Natl Acad Sci U S A 101 23 (2004) 8803-8808
95. Wilmes A., Bargh K., Kelly C., Northcote P.T., and Miller J.H. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mol Pharm 4 (2007) 269-280
96. Gaitanos T.N., Buey R.M., Diaz J.F., et al. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 64 15 (2004) 5063-5067
97. Meyer C, Ferguson D, Krauth M, Wick M, Northcote P. A novel microtubule stabilizer with potent in vivo activity against lung cancer and resistant breast cancer. In: Symposium on molecular targets and cancer therapeutics 2004;Geneva, Switzerland.
98. Reata announces licencing of novel natural products with anticancer potential. Reata Pharmaceuticals. www.reatapharma.com/news_detail.asp?id=11; 2005.
99. Buey R.M., Barasoain I., Jackson E., et al. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the Paclitaxel site predicts cytotoxicity. Chem Biol 12 12 (2005) 1269-1279
100. Tinley T.L., Randall-Hlubek D.A., Leal R.M., et al. Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res 63 12 (2003) 3211-3220